ESKATA, formerly known as A-101 40% topical solution, is the first and only
“These data highlight our robust clinical development program for ESKATA in which over 700 patients received treatment constituting the largest body of empirical research performed with respect to any potential raised SK treatment,” said Dr.
The scheduled time and location of the data presentation, as well as titles of posters on display, are as follows:
Open-Label Safety Trial SEBK-303
Poster Title: Open-Label Study of A-101, a 40% Hydrogen Peroxide Topical Solution, in Patients with Seborrheic Keratosis (Poster# 6660)
Oral Presentation: Friday, February 16 at
Location: Poster Presentation Center, The Connection, Hall A,
Presentation Title: Open-Label Study of A-101, a 40% Hydrogen Peroxide Topical Solution, in Patients with Seborrheic Keratosis
Pivotal Phase 3 Trial SEBK-302
Poster Title: Safety and Efficacy of A-101, a 40% Hydrogen Peroxide Topical Solution in Adults With Seborrheic Keratosis: Results from One of Two Identical Randomized, Double-Blind, Vehicle-Controlled Phase 3 Studies (Poster# 7454)
No Oral Presentation
Important Safety Information
ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) is for use as an in-office treatment. ESKATA is applied by your healthcare provider and is not for use at home.
Serious eye problems can happen if ESKATA gets into your eyes. If ESKATA accidentally gets into your eyes, your healthcare provider will tell you to flush them well with water for 15 to 30 minutes.
Skin reactions occurred in and around the treatment area after application of ESKATA. Some were severe, including breakdown of the outer layer of the skin (erosion), ulcers, blisters and scarring.
The most common side effects of ESKATA include itching, stinging, crusting, swelling, redness and scaling.
Tell your healthcare provider about any side effects that bother you or do not go away. Tell your healthcare provider right away if ESKATA gets into your eyes, mouth or nose during application.
Approved Use for ESKATA
ESKATA is a prescription medicine used to treat seborrheic keratoses that are raised.
You are encouraged to report negative side effects of prescription drugs to the
Please see ESKATA Full Prescribing Information and Patient Information at www.ESKATA.com.
ESKATA is the first and only
About Seborrheic Keratoses
Seborrheic keratoses (SKs) are non-cancerous skin growths that affect more than 83 million Americans and are most commonly seen in middle-aged and older adults. SKs vary in color from flesh-colored to pink, yellow, gray, tan, brown, or black; can range in size from a millimeter to a few centimeters wide; and typically have a slightly elevated, waxy or scaly appearance. The number and size of SKs tends to increase with advancing age. SKs frequently appear in highly visible locations, such as the face or neck, but can also appear anywhere on the body, except the palms, soles and mucous membranes.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris’ commercialization of ESKATA and its ability to clear raised SKs with a low risk of scarring. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially Aclaris’ reliance on third parties over which it may not always have full control, risks associated with maintaining its intellectual property portfolio and other risks and uncertainties that are described in Aclaris’ Annual Report on Form 10-K for the year ended
Vice President / Investor Relations
Source: Aclaris Therapeutics, Inc.